Screener
Generate Biomedicines, Inc. GENB Conversion Of Convertible Preferred Stock To Common Stock
Conversion Of Convertible Preferred Stock To Common Stock at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept ck0002100782:ConversionOfConvertiblePreferredStockToCommonStock.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 6:01 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Restricted cash and cash equivalents (VIE) | — | 96 |
| Long-term restricted cash | 4,032 | 4,044 |
| Cash, cash equivalents and restricted cash at end of period | 164,607 | $224,747 |
| Supplemental disclosure of noncash investing and financing information: | ||
| Purchase of property and equipment included in the accounts payable and accrued liabilities | $25 | $59 |
| Vesting of restricted stock | — | 46 |
| Reclassification of warrant liability to equity upon initial public offering | 1,568 | — |
| Conversion of convertible preferred stock to common stock | 811,826 | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s conversion of convertible preferred stock to common stock?
- Generate Biomedicines, Inc. (GENB) reported conversion of convertible preferred stock to common stock of $811.83M in Q1 2026.
- What does conversion of convertible preferred stock to common stock mean?
- Conversion Of Convertible Preferred Stock To Common Stock as reported by Generate Biomedicines, Inc. Common Stock.
Ask your AI about Generate Biomedicines, Inc.'s conversion of convertible preferred stock to common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude